Detalles de la búsqueda
1.
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development.
Br J Cancer;
128(7): 1391-1399, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36759721
2.
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study.
Future Oncol;
19(23): 1601-1611, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37577810
3.
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lancet Oncol;
23(7): 876-887, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35636444
4.
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
Br J Cancer;
127(5): 957-967, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35665778
5.
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies.
Br J Cancer;
125(6): 839-845, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34253871
6.
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study.
Clin Cancer Res;
30(2): 436-443, 2024 01 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37610454
7.
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study.
J Clin Oncol;
: JCO2302728, 2024 Jun 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38865678
8.
ShorTrip Trial: A Prospective, Multicentric Phase II Single-Arm Trial of Short-Course Radiotherapy Followed by Intensified Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer.
Clin Colorectal Cancer;
22(3): 339-343.e3, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37429749
9.
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients.
Tumori;
109(5): 481-489, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36609197
10.
Irinotecan- vs. Oxaliplatin-Based Doublets in KRASG12C-Mutated Metastatic Colorectal Cancer-A Multicentre Propensity-Score-Matched Retrospective Analysis.
Cancers (Basel);
15(11)2023 Jun 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37297026
11.
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study.
J Immunother Cancer;
11(4)2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37085190
12.
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies.
Cancers (Basel);
15(22)2023 Nov 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38001711
13.
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial.
Front Oncol;
13: 1307545, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38406172
14.
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer.
Clin Cancer Res;
29(12): 2291-2298, 2023 06 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-37022350
15.
The Evolving Landscape of Immunotherapy in Locally Advanced Rectal Cancer Patients.
Cancers (Basel);
14(18)2022 Sep 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-36139613
16.
Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability.
Cancers (Basel);
14(20)2022 Oct 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36291761
17.
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies.
Eur J Cancer;
170: 64-72, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35594613
18.
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer.
Eur J Cancer;
165: 116-124, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35231767
19.
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature.
Cancer Treat Rev;
103: 102326, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35016085
20.
Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO.
Clin Colorectal Cancer;
21(3): 220-228, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35304089